
The FDA has announced that it has chosen to approve Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Gilead’s investigational drug for the treatment of chronic …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

